Center on Health Equity and Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Partners

Press Releases

Product Approvals and Launches

Media

Clinical Spotlight

Enduring Webinars

Guidelines

Insights

Interviews

Medical World News

Microsites

News Network

OnLocation

Payer Perspectives

Peer Exchange

Podcasts

Post Conference Perspectives

Stakeholder Summit

Week in Review

Conferences

Conference Coverage

Conference Listing

Journals

Submit a Manuscript

All Journals

The American Journal of Managed Care

The American Journal of Accountable Care

Evidence-Based Oncology

Supplements and Featured Publications

Compendia

Asthma

Atopic Dermatitis

Biosimilars

Breast Cancer

COPD

COVID-19

Cholangiocarcinoma

Chronic Kidney Disease

Colorectal Cancer

DLBCL

Dermatology

Diabetes

Digital Health

Employers

Epilepsy

Heart Failure

Hematology

Hemophilia

Immuno-Oncology

Infectious Disease

Inflammation

Leukemia and Lymphoma

Liver

Lung Cancer

Lupus

Major Depressive Disorder

Medicare

Multiple Myeloma

Myasthenia Gravis

Myelodysplastic Syndromes

Oncology

Ophthalmology

Ovarian Cancer

Parkinson Disease

Prostate Cancer

Psoriasis

Pulmonary Arterial Hypertension

Rare Blood

Rare Disease

Reimbursement

Respiratory

Rheumatology

Skin Cancer

Sleep

Spinal Muscular Atrophy

Type 1 Diabetes

Vaccines

Women's Health

Events

Upcoming Webinars

CME/CE

Resources

Exclusive Content

Formulary Central

Interactive Tools

Subscribe

eNewsletter

Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.

She has a BA in English language and literature from Rutgers University. You can connect with Julia on 

Articles

Adalimumab had a slight advantage over infliximab in terms of adverse events when used to treat patients with noninfectious uveitis (NIU).

Infliximab, Adalimumab Have Similar Efficacy in Patients With Noninfectious Uveitis

Debt limit deal will not effect Medicaid; a national safety board may make health care safer; experimental hemophilia therapy reduces bleeding. 

What We’re Reading: Debt Limit Deal Reached; National Patient Safety Board; Hemophilia Therapy Results 

Quality of life (QOL) for people living with autoimmune diseases benefits from an integrated approach that considers individual immune system sensitivities and patients’ life circumstances, a new study shows.       


Digitally Tracked Data Improve QOL in Autoimmune Diseases, Long COVID  

Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.

She has a BA in English from Penn State University. You can connect with Maggie on 

Videos

Mitzi Joi Williams, MD, FAAN, medical director and CEO of Joi Life Wellness Neurology Clinic, discusses how underrepresentation of minority population patients in clinical trials became an issue and how education and raising awareness can begin to remedy it. 

Dr Mitzi Joi Williams: We Must Raise Awareness of the Importance of Clinical Trial Participation

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About Us

Contact

Editorial Staff

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Stakeholders

Academia

Health System

Payers

Providers

Topics

Institute for Value-Based Medicine

All Coverage

Event Coverage

About AJMC

AJMC Journals

Anniversary

Author Forms

Authors

Nominate a Rising Leader

View

Dialogue: Implementation of Guidelines in a Managed Care Setting

Dialogue: The Lipid-Lowering Formulary

Case Study B

Case Study C

Case Study D

Goals and Objectives

Introduction: Creating an Optimal Strategy for Lipid Management

Recent Clinical Trials and Aggressive Management of Dyslipidemic Patients

Epidemiologic Studies of Diet and Drug Therapy to Reach Target LDL-C Levels

Implementation of Guidelines in a Managed Care Setting

The Lipid-Lowering Formulary

Case Study A

Selected Abstracts

CME Quiz

Bibliography

Creating an Optimal Strategy for Lipid Management

SUPPLEMENT CONTENT

Supplements

Publications